Aims The aim of this study was to clarify whether phenytoin (PHT) stereoselective hydroxylation cosegregates with (S)-mephenytoin phenotype. Methods A single dose of PHT (100 mg) was administered orally to six healthy Japanese subjects in whom the genotype and phenotype of CYP2C19 had been determined previously. The urinary excretion profiles of the metabolites of PHT, (R)-and (S)-p-HPPH [5-(4-hydroxyphenyl)-5-phenylhydantoin] up to 36 h postdose were compared between the two groups of poor metabolizers (PMs, n=3) and extensive metabolizers (EMs, n=3) with respect to CYP2C19. CYP2C9 genotype was also determined. Results All the alleles were found to be wild type (Arg 144 Tyr 358 Ile 359 Gly 417 ) in each subject. The mean value for cumulative urinary excretion of unchanged PHT was not significantly different between the PMs and the EMs. However, recovery of (R)-p-HPPH at 36 h was 3.5-fold lower and that of (S)-p-HPPH 1.3-fold lower in PMs than in EMs. Although the mean urinary excretion values for both metabolites were significantly lower in the PMs than in the EMs, the difference between the two groups was larger for (R)-p-HPPH. A significant negative correlation was observed between the hydroxylation index of omeprazole (the ratio between the serum concentrations of omeprazole and hydroxyomeprazole in blood samples drawn 3 h after drug intake) and the log 10 0-12 h urinary recovery of (R)-p-HPPH. Conclusions In humans, the 4∞-hydroxylation of PHT is highly stereoselective towards formation of the (S)-enantiomer. Thus, (S)-hydroxylation by CYP2C9 might be the major determinant of the disposition of PHT. However, these results support the hypothesis that the stereoselective hydroxylation pathway of PHT to form (R)-p-HPPH cosegregates with the CYP2C19 metabolic polymorphism.
Introduction HPPH concentration ratio in serum samples appeared to be bimodally distributed. In view of a suspected role for (R)-Cytochrome P450 (CYP) 2C19 plays an important role in the metabolism of a number of drugs, such as omeprazole p-HPPH in the development of gingival hyperplasia, a chronic side effect of long-term PHT therapy [6] , genetic [1], diazepam [2] , proguanil [3] and several antidepressants [4] . Phenytoin (PHT) is a prochiral compound with a variation in the stereoselective 4∞-hydroxylation of PHT may have clinical significance. Therefore the aim of present chemical structure similar to mephenytoin. 5-(4-Hydroxyphenyl)-5-phenylhydantoin (p-HPPH) is the study was to clarify whether PHT stereoselective hydroxylation cosegregates with (S)-mephenytoin phenotype. major metabolite of PHT, and 4∞-hydroxylation gives rise to two enantiomers, (S)-p-HPPH and (R)-p-HPPH. p-HPPH has not been shown to possess anticonvulsant Methods properties. The pharmacokinetic profile of PHT has been well characterized in humans, with large interindividual Subjects variability in plasma drug concentrations being observed.
Six healthy Japanese volunteers were recruited from among There is evidence that the metabolic disposition of PHT pharmaceutical staff and students. They were considered to may be determined genetically. Thus, Fritz et al. [5] reported be healthy as assessed by their medical histories. Their that formation of the (R)-enantiomer of p-HPPH was genotype and phenotype with respect to CYP2C19 were clearly deficient in some Caucasian subjects, and was determined in a previous study [7] . The ratios of the associated with the mephenytoin oxidation polymorphism.
concentrations of omeprazole and hydroxyomeprazole in serum samples drawn 3 h after drug intake, and the 6.6, and (m1/m1), (m1/m1) and (m1/m2), respectively. The sensitivity of the PHT assay in the urine samples was 10 ng ml −1 , the coefficient of the intra-assay variation was The corresponding values for the three EMs were 0.08, 0.95, and 0.04, and (wt/wt), (wt/m2) and (wt/wt), 3.5%, and that of the inter-assay variation was 4.0%. The corresponding values were 10 ng ml −1 , 1.9 and 3.5% for respectively. All subjects were informed both verbally and in writing of the experimental procedure and the purpose the (S)-p-HPPH assay, and 10 ng ml −1 , 3.1 and 4.3% for the (R)-p-HPPH assay. Recoveries of PHT, (S)-p-HPPH of the study. Each subject gave written consent before the study, the protocol of which was approved by the and (R)-p-HPPH ranged from 90 to 100%. Institutional Review Board of the Clinical Pharmacology Center, Medical Co. Ltd.
Statistical analysis

Study protocol
Differences in urine parameters between the EM and PM groups were evaluated statistically using the Student's t-test. The participants came to the clinic after an overnight fast.
Spearman's rank correlation (r s ) was also used where After emptying the bladder each subject received an oral appropriate. All data are expressed as the mean (±s.d.), and dose of 100 mg of PHT (Aleviatin, Dainippon Co. Ltd, a P value of <0.05 was considered significant. Osaka, Japan) with 150 ml water. Lunch was served 4 h after the ingestion of the drug. To replace fluid loss each subject drank the same volume of water as the volume of Results urine voided after the drug ingestion. Timed urine collections were made at 2 h intervals for the first 4 h, No clinically undesirable signs or symptoms that could be attributed to the administration of PHT were recognisable followed by collections at 8, 12, 24 and 36 h. Immediately after the collection of each urine sample, its volume was throughout the study period. All subjects were homozygous for the Arg 144 , Tyr 358 , Ile 359 and Gly 417 alleles of the measured. Aliquots (10 ml ) were stored frozen at −80°C until analysed.
CYP2C9 gene. The time courses of the urinary excretion of PHT, (R)-and (S)-p-HPPH in the two phenotypes are shown in Figure 1 . Two hours after the dose of PHT, the Genotyping of CYP2C9 mean excretion of (R)-p-HPPH was 0.016±0.012% in the PM group, and 0.036±0.009% in the EM group. This Venous blood (10 ml) was obtained from all subjects, and deoxyribonucleic acid (DNA) was isolated from peripheral interphenotypic difference was observed throughout the urine collection period and was statistically significant leukocytes. Genotyping procedures for the identification of the mutations were performed by PCR amplification using (P<0.05) except after 2 h. The mean cumulative excretion of (R)-p-HPPH at 36 h was 0.52±0.19% in the PMs and primers specific for exon 3, exon 7 and exon 8 of CYP2C9 as described by Wang et al. [8] . The PCR products were 1.83±0.52% in the EMs. The urinary excretion profile of (S)-p-HPPH showed significant differences between the two sequenced with a DNA cycle sequencing kit (Takara, Shiga, Japan) according to the manufacturer's instruction (DSQ-1, groups similar to those observed with (R)-p-HPPH. The mean cumulative excretion of this metabolite at 12, 24 and Shimadzu, Kyoto, Japan).
36 h was 12.3±1.6, 28.3±4.9 and 38.3±7.4% in the PMs, and 19.9±4.8, 39.2±4.3 and 49.6±4.4%, respectively, in Assay of phenytoin and its two metabolites the EMs (p<0.05). Thus, the interphenotypic differences between (R)-and (S)-p-HPPH increased at the later The concentrations of PHT, (R)-and (S)-p-HPPH, in urine samples were measured in duplicate by high performance collection times. The mean value for the cumulative urinary excretion of (R)-p-HPPH at 36 h after drug intake was liquid chromatography (h.p.l.c.) according to the methods of Eto et al. [9] with minor modifications. 100 mm Phosphate 3.5-fold lower, whereas that of (S)-p-HPPH was 1.3-fold lower in the PMs than in the EMs. In this study, buffer (0.6 ml, pH 6.8) containing allobarbital as an internal standard was added to 0.1-0.5 ml urine. Since p-HPPH is interphenotypic difference in the urinary recovery at 36 h could be detected with power of 0.82 (R-p-HPPH) and of excreted renally after glucuronidation, the p-HPPH conjugate was hydrolysed prior to assay. After treatment of p-0.72 (S-p-HPPH) at an a of 0.05 (two-tailed test), even though the power is limited by the minimum sample size. HPPH glucuronide with 400 U glucronidase at 37°C for 6 h, 1.0 ml of the mixture was poured into an Extrelut-1
The mean urinary PHT/(S)-p-HPPH and PHT/(R)-p-HPPH ratios at 36 h were 0.008±0.002 and 0.65±0.14 in column (Merck, Darmstadt, Germany). After 10 min, the column was eluted with 3.0 ml tert-butyl methyl ether. The the PMs, and 0.005±0.002 and 0.17±0.10 in the EMs. A significant phenotypic difference ( P<0.05) in the PHT/(R)-eluate was dried and dissolved in 100 ml methanol, and 20 ml aliquots were injected into the chromatograph. A Shimadzu p-HPPH ratio (0.5±0.3, mean difference ±95% C.I.) but not in the PHT/(S)-p-HPPH ratio was observed. The LC-10A system (Shimadzu, Kyoto, Japan) equipped with an LC-10AS pump and a u.v. detector (SPD-10A) was urinary excretion profile of unchanged PHT displayed no interphenotype differences. employed. The column was LiChroCART Superspher 100 RP-18(e) (12.5 cm×4 mm) with 4 mm particle diameter There was a significant negative correlation between the serum concentration ratio of omeprazole and hydroxyomep-(Merck). The mobile phase was a mixture of 11.2 mm b-cyclodextrin in 20 mm KH 2 PO 4 and 3% acetonitrile. The razole determined 3 h after drug intake, and the log 10 12 h urinary recovery of (R)-p-HPPH (Figure 2 ; r s =−0.96, column temperature was ambient. The flow rate was 0.85 ml min −1 , and the eluate was monitored at 210 nm.
P<0.05).
Time ( it was still present, indicating a role for CYP2C9 or other Discussion form of cytochrome P450 in this reaction. More detailed studies are necessary to elucidate further the cytochrome Wide interindividual variability in the 4∞-hydroxylation of PHT, the major determinant of plasma drug concentration, P450 specificity of PHT metabolism but our present results and previous observations suggest that at least two has been well documented. Defective hydroxylation of PHT in a patient who developed severe PHT intoxication was enzymes, CYP2C19 and CYP2C9, are involved in the 4∞-hydroxylation of PHT. reported by Kutt et al. [10] , and this was suggested to be an inherited trait [11, 12] . In respect to the debrisoquine polymorphism, however, no cosegregation between debrisoThis study was partially supported by the Japan Epilepsy quine oxidation phenotype and phenytoin metabolism was Research Foundation. found [13] , and phenytoin did not competitively inhibit sparteine metabolism in human liver microsomes [14] . Our References present results have shown that the stereoselective metabolism of phenytoin cosegregates with the polymorphic HPPH ratio [15] in the PMs than in the EMs suggest that [ [16] [17] [18] , and the log 10 % urinary excretion of (R)-p-HPPH. variants with the following amino acid substitutions at
